Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 210 participants.

Also called NCT07817251

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 210 participants (planned count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07817251
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07817251. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-16 (actual); primary completion 2027-06-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
CagriSema
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct07817251
Content hash
96070012986bdfbeb3976ea80b32d4395a592e4f31234f0828afa5d8fa8f34e5